Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck

Oral Oncology

Volumn 41, Issue 9, 2005, Pages 927-933

  Begleiter, Asher ^a,b   Norman, Alia ^a,c   Leitao, Darren ^b   Cabral, Teresa ^a   Hewitt, Donna ^a   Pan, Sushu ^d   Grandis, Jennifer R ^d   Siegfried, Jill M ^e   El Sayed, Samy ^c   Sutherland, Donna ^b   Ross, David A ^b   Kerr, Paul D ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c University of Pittsburgh Medical Center ^*  (Canada)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer risk; NQO1; Polymorphisms; Squamous cell carcinoma of the head and neck

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TOBACCO;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; EPIDEMIOLOGIC METHODS; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 24644457663     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.05.004     Document Type: Article

References (41)

1. J.K. Field, D.A. Spandidos, A. Malliri, J.R. Gosney, M. Yiagnisis, and P.M. Stell Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck Br J Cancer 64 1991 573 577
2. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855 4878
3. R.J. Riley, and P. Workman DT-diaphorase and cancer chemotherapy Biochem Pharmacol 43 1992 1657 1669
4. L. Ernster DT-diaphorase: A historical review Chemica Scripta 27A 1987 1 13
5. A. Begleiter, E. Robotham, G. Lacey, and M.K. Leith Increased sensitivity of quinone resistant cells to mitomycin C Cancer Lett 45 1989 173 176
6. A. Begleiter, M.K. Leith, T.J. Curphey, and G.P. Doherty Induction of DT-diaphorase in cancer chemoprevention and chemotherapy Oncol Res 9 1997 371 382
7. A.K. Jaiswal Human NAD(P)H:quinone oxidoreductase (NQO-l) gene structure and induction by dioxin Biochemistry 30 1991 10647 10653
8. A.K. Jaiswal, P. Burnett, M. Adesnik, and O.W. McBride Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6 Biochemistry 29 1990 1899 1906
9. M. Belinsky, and A.K. Jaiswal NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues Cancer Metastasis Rev 12 1993 103 117
10. R.D. Traver, D. Siegel, and H.D. Beall Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase) Br J Cancer 75 1997 69 75
11. K.T. Kelsey, and D. Ross Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy Br J Cancer 76 1997 852 854
12. V. Misra, H.J. Klamut, and A.M. Rauth Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609 Br J Cancer 77 1998 1236 1240
13. A. Begleiter, M.K. Leith, G.P. Dohert, T.J. Digby, and S. Pan Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumour cell lines Biochem Pharmacol 61 2001 955 964
14. T. Smith, S.R.R. Musk, and I.T. Johnson Allyl isothiocyanate selectively kills undifferentiated HT29 cells in vitro and suppresses aberrant crypt foci in the colonic mucosa of rats Biochem Soc Trans 24 1996 381S
15. A. Begleiter, K. Sivananthan, T.J. Curphey, and R.P. Bird Induction of NAD(P)H quinone:oxidoreductase 1 inhibits carcinogen induced aberrant crypt foci in colons of Sprague-Dawley rats Cancer Epidemiol Biomark Prev 12 2003 566 572
16. W.A. Schulz, A. Krummeck, and I. Rosinger Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies Pharmacogenetics 7 1997 235 239
17. J.-H. Zhang, Y. Li, and R. Wang NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China World J Gastroenterol 9 2003 1390 1393
18. M. Sarbia, M. Bitzer, and D. Siegel Association between NAD(P)H: quinone oxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract Int J Cancer 107 2003 381 386
19. M.J. Lafuente, X. Casterad, and M. Trias NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors Carcinogenesis 21 2000 1813 1819
20. S.-J. Park, H. Zhao, M.R. Spitz, H.B. Grossman, and X. Wu An association between NQO1 genetic polymorphism and risk of bladder cancer Mutation Res 536 2003 131 137
21. H.-J. Menze, J. Sarmanova, and P. Soucek Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations Br J Cancer 90 2004 1989 1994
22. J.L. Wiemels, A. Pagnamenta, and G.M. Taylor A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions Cancer Res 59 1999 4095 4099
23. M. Krajinovic, H. Sinnett, C. Richer, D. Labuda, and D. Sinnett Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia Int J Cancer 97 2002 230 236
24. M.T. Smith, Y. Wang, and E. Kane Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults Blood 97 2001 1422 1426
25. T. Naoe, K. Takeyama, and T. Yokozawa Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia Clin Cancer Res 6 2000 4091 4095
26. J.-Y. Choi, K.-M. Lee, and S.-H. Cho CYP2E1 and NQO1 genotypes, smoking and bladder cancer Pharmacogenetics 13 2003 349 355
27. S. Longuemaux, C. Delomenie, and C. Gallou Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes Cancer Res 59 1999 2903 2908
28. N. Hamajima, K. Matsuo, and H. Iwata NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese Int J Clin Oncol 7 2002 103 108
29. N. Siegelmann, and K.H. Buetow Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer develoment Oncology 62 2002 39 45
30. V. Harth, S. Donat, Y. Ko, J. Abel, H. Vetter, and T. Bruning NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer Arch Toxicol 73 2000 528 531
31. M. Steiner, M. Hillenbrand, M. Borkowsi, H. Seiter, and P. Schuff-Werner 609 C->T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Lett 135 1999 67 71
32. E.S. Peters, K.T. Kelsey, and J.K. Wiencke NAT2 and NQO1 polymorphisms are not associated with adult glioma Cancer Epidemiol Biomark Prev 10 2001 151 152
33. P. Soucek, J. Sarmanova, V.N. Kristensen, M. Apltauerova, and I. Gut Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas Int Arch Occup Environ Health 75 Suppl 2002 S86 S92
34. N. Sunaga, T. Kohno, and N. Yanagitani Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility Cancer Epidemiol Biomark Prev 11 2002 730 738
35. H. Chen, A. Lum, A. Seifried, L.R. Wilkens, and L. Le Marchand Association of the NAD(P)H:quinone oxidoreductase 609C->T polymorphism with a decreased lung cancer risk Cancer Res 59 1999 3045 3048
36. E.A. Rosvold, K.A. McGlynn, E.D. Lustbader, and K.H. Buetow Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking Pharmacogenetics 5 1995 199 206
37. S.-S. Pan, G.L. Forrest, S.A. Akman, and L.-T. Hu NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells Cancer Res 55 1995 330 335
38. A. Gaedigk, R.F. Tyndale, M. Jurima-Romet, E.M. Sellers, D.M. Grant, and J.S. Leeder NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations Pharmacogenetics 8 1998 305 313
39. C. Sachse, G. Smith, and M.J.V. Wilkie A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer Carcinogenesis 23 2002 1839 1849
40. D.-H. Wu Quinone oxidoreductase gene polymorphism and genetic susceptibility to nasopharyngeal carcinoma Di Yi Jun Yi Da Xue Xue Bao (J First Mil Med Univ) 22 2002 1126 1127
41. W.-H. Jia, B.-J. Feng, Z.-L. Xu, X.-S. Zhang, P. Huang, and L.-X. Huang Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China Cancer 101 2004 363 369